Diabetes-specific interventions, such as the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists with demonstrated cardiovascular benefits, may offer new opportunities for integrated care in this high-risk population. This evidence concerns the gene SLC5A2 and diabetes mellitus.